HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp.

The purpose of this study is to test whether the stimulation of vascularization and cellular metabolism on the scalp by use of the HairMax LaserComb will produce improvement in the condition of scalp seborrheic dermatitis.

Study Overview

• Status: Completed
• Conditions: Seborrheic Dermatitis
• Intervention / Treatment: Device: HairMax LaserComb

Detailed Description

This is an open label pilot study to evaluate the effects of the low-level laser light on seborrheic dermatitis of the scalp. Dandruff assessment scores for scalps with seborrheic dermatitis will be assessed at baseline with monthly evaluations during treatment, until final assessment at end of treatment at week 12.

The trial will involve 10 patients aged 18 years and older with a diagnosis of seborrheic dermatitis. Patients will use the LaserComb device three times per week on non-consecutive days for 12 weeks. No other seborrheic dermatitis products will be used during treatment. The investigator will conduct measurements of dandruff at each study visit, as a measure of efficacy.

The trial consists of 4-5 study visits (screening/baseline, week 4, week 8 and week 12). Dandruff evaluation and adverse event assessments will be performed at each visit.

Safety analysis will be assessed based on the reports of adverse events during the study.

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • London, Ontario, Canada, N5X 2P1
      • Mediprobe Research Inc

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of seborrheic dermatitis of the scalp
• PGA of 2 (mild) or greater at baseline
• TDSS score at baseline of 2 or greater, for both scaling and inflammation
• Must agree to use of non-medicated shampoos during study period; must refrain from use of other medicated scalp products during the trial

Exclusion Criteria:

• Use of any topical or oral products that would affect assessment of the scalp SD condition, in the opinion of the primary investigator, within the following periods prior to baseline:

  • Medicated shampoos within 2 weeks of baseline
  • Topical scalp medications within 2 weeks of baseline
  • Oral medications affecting the scalp within 4 weeks of baseline
  • Other medications determined by the investigator to potentially affect the assessment of SD = washout to be determined by the investigator, as appropriate to the known medication properties
• Any current or past medical condition, including active dermatitis or any other dermatological condition, which might interfere with assessment of dandruff
• Patients using any medications that may increase photosensitivity, and thus pose a risk when undergoing LaserComb therapy
• Patients with known adverse reactions, allergy or hypersensitivity to laser light components/light sensitivity conditions
• Patients who have received any investigational drug within 30 days prior to study entry.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LaserComb; Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp	Device: HairMax LaserComb; LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of subjects achieving a Global Outcome Score (GOS) of 0, 1 or 2 at week 12	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Reduction of the Total Dandruff Sum Score (TDSS) from baseline to week 12	12 weeks
% of subjects achieving a week 12 PGA grade of '1: slight' or '0: none'	12 weeks
% of subjects achieving at least a 2-grade reduction in PGA from baseline to week 12	12 weeks

Collaborators and Investigators

• Sponsor: Lexington International, LLC
• Investigators: Study Director: Aditya Gupta, M.D., Ph.D., Mediprobe Research Inc.

Study record dates

Study Major Dates

• Study Start: January 1, 2009
• Primary Completion (Actual): September 1, 2009
• Study Completion (Actual): September 1, 2009

Study Registration Dates

• First Submitted: January 26, 2009
• First Submitted That Met QC Criteria: January 27, 2009
• First Posted (Estimate): January 28, 2009

Study Record Updates

• Last Update Posted (Estimate): June 27, 2012
• Last Update Submitted That Met QC Criteria: June 25, 2012
• Last Verified: June 1, 2012

More Information

Terms related to this study

• Keywords: seborrheic dermatitis
• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Skin Diseases, Eczematous; Sebaceous Gland Diseases; Dermatitis; Dermatitis, Seborrheic
• Other Study ID Numbers: LEX0903